Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2022 | Making clinical trials patient-friendly

Hans Scheurer • 3 Feb 2022
CAR-T Meeting 2022
General Multiple Myeloma CAR-T

Hans Scheurer, MSc, European Medicines Agency, Amsterdam, Netherlands and Myeloma Patients Europe, Brussels, Belgium, comments on the importance of involving patient groups in the development of clinical trials. Mr Scheurer explains that healthcare professionals should communicate with patients about the design of their study and ensure that it is tailored towards their preferences and unmet needs. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.

More from Hans Scheurer

3:01
Myeloma Patients Europe: aims & projects
Hans Scheurer • 3 Feb 2022

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals